Abstract | BACKGROUND: METHODS: RESULTS:
Ribavirin was tolerated well, and all completed the treatment schedule. Ribavirin decreased aminotransferase levels in all instances, and the mean value at termination decreased to half of the baseline level (P < 0.01), but the enzyme level increased after cessation of therapy in most cases. Ribavirin suppressed amounts of hepatitis C virus RNA in 4 of 9 patients, and 1 became negative during follow-up. Interferon alone (P < 0.05) or with ribavirin (P < 0.01) significantly decreased the viral population, resulting in sustained loss of viremia with normal enzyme levels in 2 of 9 and 3 of 9 patients, respectively, in each therapy during follow-up. CONCLUSIONS:
|
Authors | S Kakumu, K Yoshioka, T Wakita, T Ishikawa, M Takayanagi, Y Higashi |
Journal | Gastroenterology
(Gastroenterology)
Vol. 105
Issue 2
Pg. 507-12
(Aug 1993)
ISSN: 0016-5085 [Print] United States |
PMID | 8392957
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- RNA, Viral
- Ribavirin
- Interferon-beta
|
Topics |
- Adult
- Chronic Disease
- Female
- Hepacivirus
(genetics)
- Hepatitis C
(drug therapy, metabolism, therapy)
- Humans
- Interferon-beta
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Pilot Projects
- RNA, Viral
(blood)
- Ribavirin
(adverse effects, therapeutic use)
|